Current treatment of choice for chronic hepatitis C infection

Infection and Drug Resistance

Volumn 4, Issue 1, 2011, Pages 11-18

  Yasin, Tareq ^a   Riley, Thomas R ^a   Schreibman, Ian R ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Chronic; Hepatitis C virus; Infection; Pegylated interferon; Ribavirin; Treatment

Indexed keywords

ALPHA2B INTERFERON; FLUINDOSTATIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN;

ALOPECIA; ANEMIA; ANTIVIRAL ACTIVITY; APATHY; ARTHRALGIA; BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; DECREASED APPETITE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LOW DRUG DOSE; MIXED INFECTION; MONOTHERAPY; MYALGIA; NEUTROPENIA; NONHUMAN; PATIENT MONITORING; PREDICTION; RELAPSE; RETREATMENT; REVIEW; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS VIRULENCE; WEIGHT REDUCTION;

EID: 79952675081     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S4827     Document Type: Review

References (34)

1. Centers for Disease Control. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Recomm Rep. 1991;40(No. RR-4):1-17.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:62S-5S.
3. The National Institutes of Health Consensus Statement on Management of Hepatitis C: 2002. NIH consensus and State-of-the-Science Statements. Volume 19, Number 3, June 10-12, 2002.
4. Strader, DB, Wright, T, Thomas, DL, Seeff, LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147.
5. The National Institutes of Health Consensus Development Conference. Management of hepatitis C. Hepatology. 1997;26 Suppl 1:1S.
6. Reesink H, Bergmann J, de Bruijne J, and others. Safety and antiviral activity of SCH 900518 administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV infected patients. 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark. April 22-26, 2009. Abstract 86.
7. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology. 1997;26:57.
8. Fried MW, Shiffman, ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975.
9. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346.
10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958.
11. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database Syst Rev 2009, Issue 4. Art. No.: CD005527. DOI: 10.1002/14651858.CD005527.pub2.
12. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:897.
13. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126:703.
14. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001; 34:395.
15. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958.
16. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975.
17. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy inchronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346.
18. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol. 2006;45:204.
19. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007;14:721.
20. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49:22.
21. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med. 2009;361:580-594.
22. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon Alfa-2a Plus Ribavirin is More Effective than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology. 2010;138:116-122.
23. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med. 2004;140:370.
24. Davis GL, Wong JB, McHutchison JG, Manns MP. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645.
25. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425.
26. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451.
27. Krawitt EL, Ashikaga T, Gordon SR, et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol. 2005;43:243.
28. McGovern BH. Hepatitis in the HIV infected patient. Acquir Immure Defic Syndr. 2007;45:47-56.
29. Blackard J, Smeaton L, Hiasa Y, et al. Detection of hepatitis C virus in serum and peripheral blood mononuclear cells from HCV monoinfected and HCV/HIV co infected persons. Infect Dis. 2005;192:258-265.
30. Soriano V. Treatment of chronic hepatitis C in HIV positive individuals: Selection of candidates. Hepatol. 2006;44(suppl):S44-S48.
31. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIVInfected Patients. New Engl Med. 2004;351:438-450.
32. Milazzo L, Caramma I, Mazzali C, et al. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. Antimicrob Chemother. 2010;65:735-740.
33. Huang CF, Yang JF Dai CY, et al. Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C. Infect Dis. 2010;201:751-759.
34. Liu-Yong G, Kozal MJ. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS. 2008;22(6):449-457.